| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions
|
Cortellini, A.
|
|
|
33 |
11 |
p. 1202-1204
|
artikel
|
| 2 |
Association of tumor-infiltrating lymphocytes with survival depends on primary tumor sidedness in stage III colon cancers (NCCTG N0147) [Alliance]
|
Saberzadeh-Ardestani, B.
|
|
|
33 |
11 |
p. 1159-1167
|
artikel
|
| 3 |
Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers
|
Jahn, A.
|
|
|
33 |
11 |
p. 1186-1199
|
artikel
|
| 4 |
Editorial Board
|
|
|
|
33 |
11 |
p. iii
|
artikel
|
| 5 |
ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe
|
Vaz-Luis, I.
|
|
|
33 |
11 |
p. 1119-1133
|
artikel
|
| 6 |
ESO–ESMO fifth international consensus guidelines for breast cancer in young women (BCY5)
|
Paluch-Shimon, S.
|
|
|
33 |
11 |
p. 1097-1118
|
artikel
|
| 7 |
First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin ☆
|
Iacovelli, R.
|
|
|
33 |
11 |
p. 1179-1185
|
artikel
|
| 8 |
Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment
|
Lasagna, A.
|
|
|
33 |
11 |
p. 1207-1208
|
artikel
|
| 9 |
Molecular profiling and precision medicine in rare gastrointestinal cancers within EURACAN in the SPECTA Arcagen study (EORTC-1843): too few patients with matched treatment in Europe
|
Lamarca, A.
|
|
|
33 |
11 |
p. 1200-1202
|
artikel
|
| 10 |
Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response ☆
|
Loibl, S.
|
|
|
33 |
11 |
p. 1149-1158
|
artikel
|
| 11 |
Neoadjuvant immunotherapy in triple-negative breast cancer: lesson learnt, remaining questions
|
Bianchini, G.
|
|
|
33 |
11 |
p. 1091-1093
|
artikel
|
| 12 |
Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial ☆
|
Griesinger, F.
|
|
|
33 |
11 |
p. 1168-1178
|
artikel
|
| 13 |
Table of Contents
|
|
|
|
33 |
11 |
p. i-ii
|
artikel
|
| 14 |
Targeting the complexity of ERBB2 biology in gastroesophageal carcinoma
|
Augustin, J.E.
|
|
|
33 |
11 |
p. 1134-1148
|
artikel
|
| 15 |
The prognostic value of TILs in stage III colon cancer must consider sidedness
|
Moreno, V.
|
|
|
33 |
11 |
p. 1094-1096
|
artikel
|
| 16 |
Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay
|
McGrail, D.J.
|
|
|
33 |
11 |
p. 1204-1206
|
artikel
|
Tijdschrift beschrijving